Navigation Links
New Chemo Regimen May Benefit Ovarian Cancer Patients
Date:9/20/2009

Dose-dense treatment improved survival, but too toxic for some: study

SUNDAY, Sept. 20 (HealthDay News) -- Dose-dense chemotherapy improves survival in women with advanced ovarian cancer, Japanese researchers say.

Currently, paclitaxel and carboplatin given every three weeks is considered standard first-line chemotherapy for advanced epithelial ovarian cancer. However, dose-dense weekly treatment with paclitaxel is seen as a way to increase progression-free and overall survival in these patients, according to the new study findings.

This phase 3 study of 637 women compared the two approaches. The participants had advanced epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.

The 320 patients in the conventional regimen group received six cycles of paclitaxel (180 milligrams per meter squared; three-hour intravenous infusion). The 317 patients in the dose-dense group received paclitaxel (80 milligrams per meter squared; one-hour intravenous infusion) on days one, eight and 15. Both groups received carboplatin on day one of a 21-day cycle.

The patients in the dose-dense group had longer median progression-free survival than those in the standard treatment group (28 months versus 17 months), and longer overall survival at three years (72 percent versus 65 percent). This means that women in the dose-dense group had a 29 percent lower risk of cancer progression and a 25 percent lower risk of death, the authors explained.

Toxicity forced 113 patients in the dose-dense group and 69 patients in the conventional therapy group to stop treatment, the researchers noted. Severe anemia occurred in 214 patients (69 percent) in the dose-dense group and in 137 (44 percent) of the standard therapy group.

The survival benefits seen in the dose-dense group are rare in patients with advanced ovarian cancer, and this regimen offers a new treatment option for women with advanced epithelial ovarian cancer, concluded Dr. Noriyuki Katsumata, of the National Cancer Center Hospital in Tokyo, and colleagues.

The study, published in an upcoming print issue of The Lancet, was released online Sunday to coincide with the European Cancer Organization meeting held Sept. 20 to 24 in Berlin.

"The use of such dose-dense therapy should be decided on an individual basis together with other options for women with advanced-stage ovarian cancer," Dr. Michael A. Bookman, of the Arizona Cancer Center in Tucson, wrote in an accompanying commentary in The Lancet.

More information

The U.S. National Cancer Institute has more about ovarian cancer.



-- Robert Preidt



SOURCE: The Lancet, news release, Sept. 19, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Chemobrain -- the flip side of surviving cancer
2. Yeast unravels effects of chemotherapy drugs
3. Chemotherapy Linked to Sleep-Wake Cycle Disruptions
4. Blood Thinner May Prevent Chemo-Related Clots
5. Chemotherapy for breast cancer is associated with disruption of sleep-wake rhythm in women
6. JNCI news brief: Melanosome dynamics and sensitivity of melanoma cells to chemotherapy
7. Chemo Plus Palliative Care Reaps Benefits
8. Stray Breast Cancer Cells Yield to Post-Op Chemo
9. JNCI news brief: Antibody linked to chemotherapy drug inhibits ovarian cancer in lab
10. Radiation Plus Chemo a Good Option in Lung Cancer
11. Oral Chemotherapy Offers Patients a More Convenient, Less Invasive Treatment Option
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Chemo Regimen May Benefit Ovarian Cancer Patients 
(Date:4/26/2017)... JOHYNSTON, Iowa (PRWEB) , ... April 26, 2017 ... ... agriculture? DuPont Pioneer today launched a unique website ( CRISPRCas.pioneer.com ) that demonstrates ... plants and help farmers produce more and better food, with fewer resources. It ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... Mirroring360 Pro . This new addition to the Mirroring360 product family combines ... and business. , Mirroring360 Pro enables educators, business professionals and individuals to stream ...
(Date:4/25/2017)... ... 25, 2017 , ... A recent report from the Wisconsin ... the 2015-16 school year across Wisconsin’s public schools, charter schools, and private schools ... in student test score performance, the report’s limited analyses fail to provide answers ...
(Date:4/25/2017)... RESTON, VIRGINIA (PRWEB) , ... April 25, 2017 ... ... scientists leading the way in unveiling cutting-edge birth defects research related to Zika ... recognized by the world’s premier society for this important science. , ...
(Date:4/25/2017)... ... , ... Emergency Physician and Distinguished Professor of Emergency Medicine Bentley Bobrow will ... set to publish in summer 2017. , Dr. Bobrow, MD, FACEP, FAHA, is ... of Medicine. He also serves as Medical Director for the Bureau of Emergency Medical ...
Breaking Medicine News(10 mins):
(Date:4/24/2017)... UNION CITY, Calif. , April 24, 2017 /PRNewswire/ ... providing durability, grip, protection, and comfort, announces the release ... the Powerform S8+. This most recent example of leading ... high density grip pattern for 200% more tactile grip ... in user protection and durability. With TracTek and a ...
(Date:4/20/2017)... , April 20, 2017  Zimmer Biomet Holdings, Inc. ... healthcare, today announced that it will be participating in ... at the InterContinental Hotel in Boston, Massachusetts ... will present at 11:20 a.m. Eastern Time. ... via Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com ...
(Date:4/20/2017)...   ZappRx, Inc ., a digital health company focused ... announced it closed $25 million in Series B funding led ... in Seattle that is part of ... Series B round included participation from SR One , ... GV (formerly Google Ventures). As part of the financing, ...
Breaking Medicine Technology: